Serum microRNAs predict response of patients with chronic hepatitis B to antiviral therapy

Tan, Bi-Bo; Liu, Mei; Wang, Liming; Wang, Jinhuan; Xiong, Fang; Bao, Xuli; Gao, Yao; Yu, Lele; Lu, Jun

doi:10.1016/j.ijid.2021.05.015

Cited by 9 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, Zhang et al [ 38 ] showed that a model based on 11 response-related miRNAs could predict the response to IFN-α in patients with CHB. Another model was built by Tan et al [ 39 ] using 11 other miRNAs. Age, sex, ALT levels, bile acids, obesity, insulin resistance, alcohol consumption, and anti-IFN antibodies are also involved in the response to IFN-α in patients with CHB [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

Prediction Model for the Clearance of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis B before Interferon Therapy: A Prospective Case–Control Study

Geng,

Ma,

Jin

et al. 2024

Diagnostics

View full text Add to dashboard Cite

To evaluate the prediction model comprised of patients’ laboratory results and single-nucleotide polymorphism (SNP) markers of host gene for the clearance of hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B (CHB) who underwent interferon (IFN)-α therapy, this prospective case–control study enrolled 131 patients with CHB who underwent IFN-α-based regimens in our hospital between January 2015 and September 2019. Among them, 56 cases were without HBsAg clearance, while the other 75 cases had HBsAg clearance. Multivariable logistic regression analysis showed that CYP27B1 rs4646536 (odd ratio [OR] = 0.155, 95% CI: 0.030–0.807, p = 0.027), PAK4 rs9676717 (OR = 11.237, 95% CI: 1.768–71.409, p = 0.010), IL28B rs12979860 (OR = 0.059, 95% CI: 0.006–0.604, p = 0.017), baseline HBsAg (OR = 0.170, 95% CI: 0.040–0.716, p = 0.016), and HBeAg status (OR = 3.971, 95% CI: 1.138–13.859, p = 0.031) were independently associated with HBsAg clearance. The model that included rs3077, rs4646536, rs9676717, rs2850015, rs12979860, baseline HBsAg, HBeAg status, and HBV DNA had the best prediction performance for HBsAg clearance prediction, with AUC = 0.877, 80% sensitivity, and 81% specificity. In conclusion, laboratory results and gene polymorphisms before treatment might have a good predictive value for HbsAg clearance after IFN-α treatment in CHB.

show abstract

Section: Discussionmentioning

confidence: 99%

Prediction Model for the Clearance of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis B before Interferon Therapy: A Prospective Case–Control Study

Geng,

Ma,

Jin

et al. 2024

Diagnostics

View full text Add to dashboard Cite

show abstract

“…There are fewer reports concerning hsa-miR-320a-3p . In the study of hepatitis B, hsa-miR-320a-3p was negatively correlated with HBV-DNA quantity and hsa-miR-320a-3p increased significantly after HBV antiretroviral therapy . Another biomarker study suggests that plasma and the exosomal miR-320 family may serve as potential biomarkers for the diagnosis of methamphetamine use disorders .…”

Section: Discussionmentioning

confidence: 99%

MicroRNA hsa-miR-320a-3p and Its Targeted mRNA FKBP5 Were Differentially Expressed in Patients with HIV/TB Co-Infection

Li,

Bao,

Gao

et al. 2023

ACS Infect. Dis.

View full text Add to dashboard Cite

Among the PLWH (people living with HIV) population, the risk of developing active tuberculosis (TB) is increasing. Active TB also accelerates the deterioration of PLWH’s immune function and is one of the leading causes of death in the PLWH population. So far, accurate diagnosis of active TB in the PLWH population remains challenging. Through data analysis of HIV/TB co-infection in the GEO database, the differentially expressed genes as well as their related microRNA (miRNA) were acquired and were further verified through clinical blood samples. Dual-luciferase assay was used to verify the mechanism of miRNA on mRNA. The enrichment of immune cells in database patient samples was analyzed by bioinformatics and finally verified by blood routine data. Our study found that FKBP5 (FK506 binding protein 5) was highly expressed in the HIV/TB co-infection group; hsa-miR-320a-3p was highly expressed in the HIV infection group but decreased in the HIV/TB co-infection group. Dual-luciferase assay results showed that hsa-miR-320a-3p mimics significantly reduced the relative luciferase activity of the WT-FKBP5 group; however, this phenomenon was not observed in the MUT-FKBP5 group. At the same time, as a key molecule of the immune-related pathway, FKBP5 is highly correlated with the amount of neutrophils, which provides a new suggestion for the treatment of the HIV/TB co-infection population. Our study found that hsa-miR-320a-3p can decrease FKBP5 expression, suggesting a potential regulatory role for FKBP5. The involvement of FKBP5 and its related molecule hsa-miR-320a-3p in HIV/TB co-infection proposes them as potential biomarkers for the diagnosis of active TB in the PLWH population.

show abstract

“…Consequently, they might serve as diagnostic biomarkers based on their presence and levels in patient samples [185][186][187], offer insights into disease prognosis through their different expression during infection [188], and present opportunities as therapeutic targets for the development of antiviral drugs (i.e., anti-miR therapy) [189,190]. Furthermore, their use could extend to monitoring treatment response by evaluating the treatment efficacy [191].…”

Section: Micrornas and Hepatitis B Virusmentioning

confidence: 99%

Hepatitis B Virus and microRNAs: A Bioinformatics Approach

Zulian,

Fiscon,

Paci

et al. 2023

IJMS

View full text Add to dashboard Cite

In recent decades, microRNAs (miRNAs) have emerged as key regulators of gene expression, and the identification of viral miRNAs (v-miRNAs) within some viruses, including hepatitis B virus (HBV), has attracted significant attention. HBV infections often progress to chronic states (CHB) and may induce fibrosis/cirrhosis and hepatocellular carcinoma (HCC). The presence of HBV can dysregulate host miRNA expression, influencing several biological pathways, such as apoptosis, innate and immune response, viral replication, and pathogenesis. Consequently, miRNAs are considered a promising biomarker for diagnostic, prognostic, and treatment response. The dynamics of miRNAs during HBV infection are multifaceted, influenced by host variability and miRNA interactions. Given the ability of miRNAs to target multiple messenger RNA (mRNA), understanding the viral–host (human) interplay is complex but essential to develop novel clinical applications. Therefore, bioinformatics can help to analyze, identify, and interpret a vast amount of miRNA data. This review explores the bioinformatics tools available for viral and host miRNA research. Moreover, we introduce a brief overview focusing on the role of miRNAs during HBV infection. In this way, this review aims to help the selection of the most appropriate bioinformatics tools based on requirements and research goals.

show abstract

Serum microRNAs predict response of patients with chronic hepatitis B to antiviral therapy

Cited by 9 publications

References 29 publications

Prediction Model for the Clearance of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis B before Interferon Therapy: A Prospective Case–Control Study

Prediction Model for the Clearance of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis B before Interferon Therapy: A Prospective Case–Control Study

MicroRNA hsa-miR-320a-3p and Its Targeted mRNA FKBP5 Were Differentially Expressed in Patients with HIV/TB Co-Infection

Hepatitis B Virus and microRNAs: A Bioinformatics Approach

Contact Info

Product

Resources

About